Antibiotic Resistance in Pediatric Urinary Tract Infections

Current Infectious Disease Reports

Volumn 18, Issue 12, 2016, Pages

  Stultz, Jeremy S ^a   Doern, Christopher D ^b   Godbout, Emily ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Extended spectrum beta lactamases; Microbial sensitivity tests; Pediatric; Urinary tract infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAZOLIN; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MONOBACTAM DERIVATIVE; NALIDIXIC ACID; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TICARCILLIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PROTEUS MIRABILIS; REVIEW; RISK FACTOR; URINARY TRACT INFECTION;

EID: 84992130101     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-016-0555-4     Document Type: Review

References (42)

1. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008;27(4):302–8. doi:10.1097/INF.0b013e31815e4122.
2. Freedman AL, Urologic Diseases in America Project. Urologic diseases in North America Project: trends in resource utilization for urinary tract infections in children. J Urol. 2005;173(3):949–54.
3. Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol. 2013;190(1):222–7. doi:10.1016/j.juro.2013.01.069.
4. Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013;163(5):1417–21. doi:10.1016/j.jpeds.2013.06.078.
5. Copp HL, Shapiro DJ, Hersh AL. National ambulatory antibiotic prescribing patterns for pediatric urinary tract infection, 1998–2007. Pediatrics. 2011;127(6):1027–33. doi:10.1542/peds.2010-3465.
6. Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2014;7, CD003772. doi:10.1002/14651858.CD003772.pub4.
7. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595–610. doi:10.1542/peds.2011-1330.
8. Clinical and Laboratory Science Institute. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015;Wayne, PA, USA: Clinical and Laboratory Standards Institute.
9. European Committee on Antimicrobial Susceptibility Testing. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015;Version 5.0.
10. Rose L, Coulter MM, Chan S, Hossain J, Di Pentima MC. Trends of fluoroquinolone-resistant Escherichia coli amongst urinary isolates in children: a 10 year surveillance study. J Med Microbiol. 2015;64(7):778–81. doi:10.1099/jmm.0.000072.
11. •Bitsori M, Maraki S, Galanakis E. Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis. Pediatr Nephrol. 2014;29(6):1053–8. doi:10.1007/s00467-013-2719-x. This study looked at antimicrobial resistance over a 12-year period in Greece and found significant increases in isolation of resistant organisms over the study period in pediatric patients. The study also found that prior antibiotic exposure was an independent risk factor for acquiring a UTI with a resistant organism.
12. Mohammad-Jafari H, Saffar MJ, Nemate I, Saffar H, Khalilian AR. Increasing antibiotic resistance among uropathogens isolated during years 2006–2009: impact on the empirical management. Int Braz J Urol. 2012;38(1):25–32.
13. ••Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016;352:i939. doi:10.1136/bmj.i939. This study was a meta-analysis of global E. coli UTI antimicrobial resistance in pediatric patients. It found significant differences between countries, with higher resistance rates in countries with over the counter antibiotics. Also, the meta-analysis found a significant association with prior antibiotic exposure up to 6 months and increased antibiotic resistance.
14. Boggan JC, Navar-Boggan AM, Jhaveri R. Pediatric-specific antimicrobial susceptibility data and empiric antibiotic selection. Pediatrics. 2012;130(3):e615–22. doi:10.1542/peds.2012-0563.
15. McGregor JC, Quach Y, Bearden DT, Smith DH, Sharp SE, Guzman-Cottrill JA. Variation in antibiotic susceptibility of uropathogens by age among ambulatory pediatric patients. J Pediatr Nurs. 2014;29(2):152–7. doi:10.1016/j.pedn.2013.09.001.
16. Keren R, Shaikh N, Pohl H, et al. Risk factors for recurrent urinary tract infection and renal scarring. Pediatrics. 2015;136(1):e13–21. doi:10.1542/peds.2015-0409.
17. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics. 2010;126(6):1084–91. doi:10.1542/peds.2010-0685.
18. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007;298(2):179–86.
19. Mantadakis E, Tsalkidis A, Panopoulou M, et al. Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece. Int Urol Nephrol. 2011;43(2):549–55. doi:10.1007/s11255-010-9768-x.
20. Jakovljevic E, Ilic K, Jelesic Z, Konstantinidis G. A one-year prospective study on the antibiotic resistance of E. coli strains isolated in urinary specimens of children hospitalized at the University Pediatric Medical Center in Novi Sad, Serbia. Infection. 2013;41(6):1111–9. doi:10.1007/s15010-013-0493-0.
21. Rezaee MA, Abdinia B. Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to UTI: a referral hospital-based study in northwest of Iran. Medicine (Baltimore). 2015;94(39), e1606. doi:10.1097/MD.0000000000001606.
22. Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics. 2010;125(4):664–72. doi:10.1542/peds.2009-1527.
23. Caracciolo A, Bettinelli A, Bonato C, et al. Antimicrobial resistance among Escherichia coli that cause childhood community-acquired urinary tract infections in northern Italy. Ital J Pediatr. 2011;37:3. doi:10.1186/1824-7288-37-3.
24. Sakran W, Smolkin V, Odetalla A, Halevy R, Koren A. Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection. Clin Pediatr (Phila). 2015;54(5):479–483. doi: 10.1177/0009922814555974.
25. Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014;370(25):2367–76. doi:10.1056/NEJMoa1401811. This was the largest and likely highest quality prospective study regarding the use of prophylactic antibiotics to prevent UTI for pediatric patients with vesicoureteral reflux. Important to this review, patients on prophylactic antibiotics had higher rates of UTIs due to a resistant organism.
26. Ashkenazi-Hoffnung L, Melamed N, Ben-Haroush A, Livni G, Amir J, Bilavsky E. The association of intrapartum antibiotic exposure with the incidence and antibiotic resistance of infantile late-onset serious bacterial infections. Clin Pediatr (Phila). 2011;50(9):827–33. doi:10.1177/0009922811406260.
27. Nelson CP, Hoberman A, Shaikh N, et al. Antimicrobial resistance and urinary tract infection recurrence. Pediatrics. 2016;137(4). doi: 10.1542/peds.2015-2490.
28. •Fan NC, Chen HH, Chen CL, et al. Rise of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47(5):399–405. doi:10.1016/j.jmii.2013.05.006. This was a study looking at ESBL production over a 5-year period in pediatric urinary isolates. Mild increases in resistance over time were noted, and risk factors for ESBL UTI pathogens were identified including recent hospitalizations, neurologic diseases, and recent antibiotic exposure.
29. Kizilca O, Siraneci R, Yilmaz A, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012;54(6):858–62. doi:10.1111/j.1442-200X.2012.03709.x.
30. Tratselas A, Iosifidis E, Ioannidou M, et al. Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J. 2011;30(8):707–10. doi:10.1097/INF.0b013e31820d7ec4.
31. Degnan LA, Milstone AM, Diener-West M, Lee CK. Extended-spectrum beta-lactamase bacteria from urine isolates in children. J Pediatr Pharmacol Ther. 2015;20(5):373–7. doi:10.5863/1551-6776-20.5.373.
32. Navidinia M, Peerayeh SN, Fallah F, Bakhshi B, Sajadinia RS. Phylogenetic grouping and pathotypic comparison of urine and fecal Escherichia coli isolates from children with urinary tract infection. Braz J Microbiol. 2014;45(2):509–14.
33. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964–99. doi:10.1542/peds.2012-3488.
34. Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1):e262–80.
35. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–502. doi:10.1542/peds.2014-2742.
36. Chen PC, Chang LY, Lu CY, et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect. 2014;47(6):478–83. doi:10.1016/j.jmii.2013.07.011.
37. Bactrim(R) [package insert]. Philadelphia, PA; Mutual Pharmaceutical Company, INC:2013.
38. Ancef (R) [package insert]. Research Triangle Park, NC; GlaxoSmithKline:2004.
39. Lee B, Kang SY, Kang HM, et al. Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Chemother. 2013;45(4):415–21. doi:10.3947/ic.2013.45.4.415.
40. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15:414-015-1153-z. doi: 10.1186/s12879-015-1153-z.
41. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34(9):1165–9.
42. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583–90.